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ABSTRACT 
A major concern during formulation development has been to enhance the dissolution 
rate and bioavailability of poorly water-soluble drugs.[1],[2] Amorphous forms of APIs have 
attracted considerable attention as amorphous forms tend to exhibit significantly higher levels of 
supersaturation in aqueous media when compared to the crystalline forms.[3],[4] For drugs which 
bioavailability is limited by aqueous solubility (biopharmaceutical classification system (BCS) 
class II drugs), which is a significant number of recently discovered drug candidates, the 
improved solubility may lead to enhanced bioavailability.[5-7] Oral absorption of APIs depends 
on two broad, but crucial, events, namely drug solubilization and gastrointestinal permeation.[8] 
Amorphous solid dispersions have been widely investigated to increase the gastrointestinal 
permeability, and the roles played by polymers and other excipients were also studied.[9],[10] 
However, even after 40 years of active research there have not been many commercial 
products have reached the market based on amorphous solid dispersion technology.  [11, 12] The 
primary reason for this is a combination of the stability and scale up issues associated with this 
approach, which has been reported by several authors.[13-15] Hot-melt extrusion currently stands 
as the most promising approach for solving the scale-up issues associated with amorphous solid 
dispersion systems.[16] Unfortunately, amorphous solid dispersion systems still face the issue that 
the amorphous form is, in general, thermodynamically unstable relative to its crystalline 
counterpart(s), [17], [18] and therefore may ultimately result in unacceptable changes in the API’s 
physical properties. [19] The most common approach of preserving the solubility/bioavailability 
enhancement imparted by the high-energy amorphous form is to kinetically stabilize the drug 
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substance in the amorphous state for the duration of the anticipated shelf life. Amorphous solid 
dispersions can be stabilized as such if there exists a sufficient energy barrier provided by the 
polymer(s) with a high glass transition temperature, or by way of molecular interactions between 
the API and polymeric carriers, such as hydrogen bonding. So the study to evaluate and enhance 
the physical stability of amorphous solid dispersions is with great importance for the 
pharmaceutical industry. This thesis would focus on the evaluation and enhancement of the 
physical stability of amorphous solid dispersion.   
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CHAPTER 1 
INTRODUCTION 
A major concern during formulation development has been to enhance the dissolution 
rate and bioavailability of poorly water-soluble drugs.[1],[2] The amorphous forms of APIs have 
attracted considerable attention as the amorphous forms tend to exhibit significantly higher levels 
of supersaturation in aqueous media when compared to the crystalline forms.[3],[4] For drugs 
which bioavailability is limited by aqueous solubility (biopharmaceutical classification system 
(BCS) class II drugs), which is a significant number of recently discovered drug candidates, the 
improved solubility may lead to enhanced bioavailability.[5-7] Oral absorption of APIs depends 
on two broad, but crucial, events, namely drug solubilization and gastrointestinal permeation.[8] 
Amorphous solid dispersions have been widely investigated to increase the gastrointestinal 
permeability, and the roles played by polymers and other excipients were also studied.[9],[10] 
However, even after 40 years of active research there have not been many commercial 
products that have reached the market based on amorphous solid dispersion technology. [11, 12] 
The primary reason for this is a combination of the stability and scale up issues associated with 
this approach, which has been reported by several authors.[13-15] Hot-melt extrusion currently 
stands as the most promising approach for solving the scale up issues associated with amorphous 
solid dispersion systems.[16] Unfortunately, amorphous solid dispersion systems still face the 
issue that the amorphous form is, in general, thermodynamically unstable relative to its 
crystalline counterpart(s), [17], [18] and therefore may ultimately result in unacceptable changes 
in the API’s physical properties. [19] The most common approach of preserving the
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solubility/bioavailability enhancement imparted by the high-energy amorphous form is to 
kinetically stabilize the drug substance in the amorphous state for the duration of the anticipated 
shelf life. Amorphous solid dispersions can be stabilized as such if there exists a sufficient 
energy barrier provided by the polymer(s) with a high glass transition temperature, or by way of 
molecular interactions between the API and the polymeric carrier, such as hydrogen bonding. So 
the study to evaluate and enhance the physical stability of the amorphous solid dispersions is 
with great importance for the pharmaceutical industry. 
Solid dispersions were initially defined as a solid formulation system in which one or 
more active pharmaceutical ingredients (APIs) are dispersed into one inert carrier by Chiou and 
Riegelman[20]. According to the molecular arrangement of the API inside the carrier matrix and 
the physical state of polymer carriers, solid dispersion could be further classified into three 
categories, crystalline solid dispersion, amorphous solid dispersion and amorphous solid 
solution[1, 21, 22] (Figure 1-1). The carrier, commonly polymers, could be amorphous, semi-
crystalline or crystalline, while the API(s) could be either molecularly dispersed into the matrix 
or dispersed as aggregates. In a crystalline solid dispersion system, multiple phases will exist 
simultaneously, which can be identified by differential scanning calorimetry (DSC) with a glass 
transition temperature (Tg) corresponding to the carrier and a melting endotherm (Tm) 
representing the crystalline drug. Therefore, a solid crystalline dispersion is also referred to as a 
solid crystalline suspension[1].  
The solubility of a drug substance can be enhanced by the approach of breaking down the 
size of drug particles into micro or nano region [23]. The amorphous solid dispersion is 
generated when the drug is converted into an amorphous state and dispersed throughout the 
carrier matrix by heating or physical energy input; however, they have a tendency to revert to 
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their more stable, lower energy level crystalline forms from a thermodynamic standpoint. At the 
same time, a kinetically induced recrystallization will also occur since the amorphous solid 
dispersion often contains a drug-concentrated region [22, 24]. In a solid solution, which can be 
defined as a particular subgroup of amorphous solid dispersion, the drug substance is 
molecularly dispersed into the carrier with only one single glass transition temperature observed 
in DSC. 
 
Figure 1-1 The three possible structures of a drug/polymer solid dispersion where hexagonal 
symbols represent drug molecules and curvy lines represent polymer chains. [2] 
 
Basically, fusion-based method and solvent-based method were the two main type of 
methodologies to manufacture the solid dispersion systems in pharmaceutical field [22, 24, 25]. 
A solid dispersion can be prepared by a fusion-based method simply by heating the drug-carrier 
mixture along with other formulation additives to a temperature above their glass transition 
temperature, melting point or eutectic point, and then followed by cooling at a controlled rate[26-
32]. A prerequisite for any material to be processed by this method is thermal stability [24, 25, 
33]. Moreover, the miscibility and compatibility between drug and carrier needs to be seriously 
considered. The high viscosity of a molten carrier can lead to phase separation and result in an 
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inhomogeneous dispersion which will further threaten the stability of the final products[34]. In 
terms of a solvent-based method, the hydrophobic drug substances will dissolve with the 
hydrophilic carriers into their common solvent which will be evaporated [35-47]. Compared to a 
fusion-based method, this type of technology is often operated at a lower temperature which is 
more suitable for heat sensitive compounds. However, it is not very straightforward to find a 
common solvent for the rapidly increasing NCEs and carriers[22]. Moreover, it is always a 
hurdle to eliminate the solvent residue in the solid dispersions.  
Hot melt Extrusion has been used in the manufacturing process for plastics and food 
since the 1930s [49]. HME has been shown by a number of studies to be useful in the production 
of pharmaceutical products using pellets, granules, mini-tablets, transmucosal, and transdermal 
delivery systems and implants. Furthermore, HME is a continuous manufacturing process that 
does not require drying or discontinuous steps in processing, making it extremely efficient. 
There are two types of extrusion, wet and dry, that can be used for extrusion processing. 
With wet extrusion, the ingredients are mixed with a solvent such as water or alcohol which 
activates a binder and forms a wet mass, which is extruded through a sieve. Pellets are created by 
cutting and spheronizing the strands which result from extrusion through a sieve. The ripening 
action of the excipients during wet extrusion produces a uniform product with a better finish than 
dry-extruded products  [50]. Wet extrusion is also preferable for use with heat-sensitive drugs 
and excipients because it reduces localized heat build-up. In contrast to wet extrusion, dry 
extrusion does not use solvents, but rather utilizes a thermoplastic agent which forms a 
homogenous matrix with the compounds when processed with a hot melt extruder. 
Spray drying is a unit operation capable of transforming solutions or suspensions into a 
solid product. The first use of drying of products from an atomized liquid stream was already 
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described in a patent from Percy in 1872. Since then, a tremendous development of the spray 
drying process with the refinement in the hardware and equipment configuration and improved 
understanding of fluid dynamics has made it versatile technique operational in diverse industrial 
fields ranging from food and dairy processing, ceramics, paints, fertilizers, detergents and 
pharmaceutical industry. In the pharmaceutical field, spray drying is a well utilized unit 
operation employed for simple drying operations to particle engineering of bulk active 
pharmaceutical ingredients (API) and excipient and pulmonary formulations, granulation, 
encapsulation, etc. Besides, it is also used for processing vitamins and biopharmaceutical 
products such as peptides and proteins. One of the characteristics of a spray drying process is the 
very fast solvent evaporation. This makes it interesting with respect to preparation of amorphous 
solid dispersions: using the improved Avrami equation was utilized to evaluate the 
recrystallization kinetics for several amorphous solid dispersion systems including fenofibrate 
with different grades of hydroxypropylcellulose (Klucel™ LF/EF/ELF); investigating the effects 
of polymeric carrier, HME processing and other downstream processing parameters on the 
moisture sorption properties of amorphous solid dispersions; studying the impact of commonly 
used surfactants and polymers on the stability of amorphous solid dispersion suspensions using a 
Nikon polarized microscopy equipped with an automatic stage. 
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CHAPTER 2 
EVALUATION OF THE RECRYSTALLIZATION KINETICS OF HOT MELT 
EXTRUDED POLYMERIC SOLID DISPERSIONS USING AN IMPROVED AVRAMI 
EQUATION 
 
2.1 Introduction 
Hot-melt extrusion currently stands as the most promising approach for solving the scale 
up issues associated with amorphous solid dispersion systems.[16] Unfortunately, amorphous 
solid dispersion systems still face the issue that the amorphous form is, in general, 
thermodynamically unstable relative to its crystalline counterpart(s), [17], [18] and therefore may 
ultimately result in unacceptable changes in the API’s physical properties. [19] The most common 
approach of preserving the solubility/bioavailability enhancement imparted by the high-energy 
amorphous form is to kinetically stabilize the drug substance in the amorphous state for the 
duration of the anticipated shelf life. Amorphous solid dispersions can be stabilized as such if 
there exists a sufficient energy barrier provided by the polymer(s) with a high glass transition 
temperature, or by way of molecular interactions between the API and the polymeric carrier, 
such as hydrogen bonding.   
The most commonly used methods of evaluating the physical stability of these dispersed 
systems are short and long term stability tests in accordance to ICH guidance.[51] However, 
during the research and development process of a new solid dispersion drug product, hundreds of 
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formulations need to be evaluated, which is neither cost nor time efficient. Fortunately, the 
recrystallization process of the drug-polymer system can be quantitatively described by kinetics 
models.[52-54] Among these models, the Avrami model/equation is most frequently used to 
express and predict the solid-state recrystallization processes.  
α(t) = 1 − exp⁡(−k𝑡𝑛)                                        (Equation 1) 
Where the⁡α(t) is relative crystallinity, k represents the recrystallization rate constant and 
n is the Avrami exponent.  
The kinetic description of crystallization processing is composed of two main 
independent procedures: nucleation and crystal growth. The Avrami equation has been used to 
model crystallization kinetics for decades; however, one of the primary assumptions inherent in 
this equation is that the nucleation rate is a constant. Treating the nucleation process as such 
leads to an over-prediction in the recrystallization rate. This becomes particularly apparent 
during the later stages of the process. In our previous study,[55] an improved description of the 
nucleation rate was proposed that is proportional to the amorphous fraction.  
𝐽(t) = 𝐽0(1 − α(t))                                          (Equation 2) 
Where the 𝐽(t)  term is the nucleation rate of sample at time of t, 𝐽0  is the initial 
nucleation rate, and 1 − α(t) is a function of the time of the experiment.  
The improved kinetic equation enables enhanced predictability by using the experimental 
date of formulations under high temperature and high RH conditions to predict the performance 
of formulations under ambient conditions, which could, in turn, save a great deal of time and 
expense in terms of the formulation screening. 
In this study, the improved Avrami equation was utilized to evaluate the recrystallization 
kinetics for several amorphous solid dispersion systems including fenofibrate with different 
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grades of hydroxypropylcellulose (Klucel™ LF/EF/ELF). Fenofibrate is an agonist of the 
nuclear per-oxisome proliferator-activated receptor α. It reduces the blood triglyceride levels and, 
to a lesser extent, the total cholesterol and low-density lipoprotein (LDL) cholesterol levels.[56] 
Fenofibrate is practically insoluble in water which as a result of being a neutral and lipophilic 
molecule with a log P value of 5.2.[57], [58] Hydroxypropylcellulose (KlucelTM HPC) is a nonionic 
water-soluble cellulose ether, with a remarkable combination of properties including organic 
solvent solubility, thermoplasticity, and surface activity.[57] KlucelTM HPC has been widely used 
in solid dispersion formulations to control drug release,[59] inhibit drug recrystallization, [60]and 
also serve as a granulation binder.[61]  
The solid dispersion systems of fenofibrate with different grades of HPC (Klucel™) were 
compared to investigate the influence of polymer molecular weight on the physical stability of 
the amorphous systems. Compared to the original Avrami equation, the improved Avrami 
equation model performance was examined and validated by comparing the predicted values 
with experimental data. The effects of polymer content, temperature and relative humidity on the 
recrystallization rate were also investigated by the improved Avrami equation. To the best of our 
knowledge, this is the first study using this kinetics equation to evaluate the physical stability of 
amorphous solid dispersions prepared by hot melt extrusion. 
2.2 Materials and methods 
2.2.1 Materials 
Hydroxypropylcellulose (Klucel™; grades LF/EF/ELF) was kindly donated by 
ASHLAND Specialty Products (Wayne, NJ, USA) and fenofibrate was purchased from 
Aurobindo Pharma Ltd. (Hyderabad, India). Reagent grade methanol was purchased from 
Sigma–Aldrich (St. Louis, MO, USA). 
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2.2.2 Methods 
2.2.2.1 Preparation of amorphous solid dispersions using hot-melt extrusion 
Amorphous solid dispersions of fenofibrate and Klucel™ LF/EF/ELF were prepared 
using hot-melt extrusion technology. The extrusion temperature range was determined by 
Thermal gravimetric analysis (TGA). The API and polymer were mixed in a V-cone blender 
(MaxiBlendTM, GlobePharma) at 30 rpm for 20 min and then extruded with a co-rotating twin-
screw extruder (Process 11, ThermoFisher Scientific) into uniform rod extrudates at an extrusion 
temperature range of 120℃  to 130℃  based on the molecular weight of Klucel™ and a screw 
speed of 100 rpm. The feed rate was 12 g/min so that the extruder % torque indicator was in a 
safe range of 40-50%. The extrudates were milled using a comminuting Fitz Mill (Model#L1A, 
Fitzpatrick Company, IL) at a speed of 3600 rpm using a 0.0232 inch-sieve. Each formulation 
and its process parameters are shown in Table 2-1.  
Table 2-1. Composition of solid dispersions and hot melt extrusion parameters for each 
formulation. 
Content of 
Fenofibrate (%) 
Polymer Carrier 
Temp. (°C) 
Screw Speed 
(rpm) 
Torque 
(%) 
Content (%) Grade 
20 80 ELF 120 100 35-45 
15 85 ELF 120 100 35-45 
10 90 ELF 120 100 40-50 
10 90 LF 130 100 40-50 
10 90 EF 125 100 40-50 
 
2.2.2.2 Thermal gravimetric analysis (TGA) 
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TGA studies were performed on Perkin Elmer Pyris 1 TGA with the Pyris software. 3-5 
mg samples were heated at heating rate of 20℃ /min from 20℃  to 300℃ . 
2.2.2.3 Differential scanning calorimetry (DSC) 
DSC was utilized to measure the melting enthalpy of the solid dispersions. Samples were 
weighed (3-5 mg) in an aluminum sample pan and hermetically sealed at each time point using a 
heating rate of 20℃ /min from -40℃  to 180℃  (Perkin Elmer, Diamond DSC). The nitrogen 
purge rate was 20 mL/min. An empty pan was used as reference. Measurements were repeated 
three times. An Indium standard was used for calibration. 
2.2.2.4 HPLC-UV Analysis 
A Waters HPLC-UV system (Waters Corp, Milford, MA), equipped with a Luna 5um C18 
100Å  column (Phenomenex, US), was used at a detection wavelength of 286 nm. The mobile 
phase consisted of acetonitrile and phosphoric acid in water (pH=2.5) at a ratio of 85:15 (v/v). 
The flow rate was maintained at 1.0 mL/min. The retention time of fenofibrate was 6 minutes. 
The injection volume was 20 μL. All of the HPLC data was analyzed using Empower V. 
software.  
2.2.2.5 Evaluation of crystallinity on hot-melt extrudates 
The freshly extruded samples were stored in stability chambers with different 
temperature (±0.1℃) and relative humidity (±1%) conditions, which were predetermined for 
different formulations (Temperature: 40, 50, 60℃  and %RH: 10, 40, 70). Samples were removed 
from the chambers at each sampling time point and the degree of recrystallization was measured 
by DSC. The absolute percentage of crystallinity, x (t), could be determined by the ratio of 
melting enthalpies from recrystallized fenofibrate over the melting enthalpies of the physical 
mixture of fenofibrate and polymeric carrier. The relative crystallinity, α(t), was determined by 
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the ratios of the melting enthalpies of sample with the final melting enthalpy without any change. 
The equations[62] are listed below: 
𝑥(𝑡) =
∆𝐻(𝑡)
∆𝐻(𝑃.𝑀.)
                                              (Equation 3) 
Where ∆𝐻(𝑡) is the melting enthalpy of the recrystallized solid dispersion sample and the 
∆𝐻(𝑃.𝑀. ) represents the melting enthalpies of physical mixtures of the API and polymers for 
each formulation. 
The relative crystallinity, 𝛼(𝑡),⁡was calculated using the following equation: 
𝛼(𝑡) =
∆𝐻(𝑡)
𝛥𝐻∞
                                                (Equation 4) 
Where ∆𝐻∞ is the final melting enthalpy of solid dispersion sample for a certain stress 
condition (this value was constant and did not change during testing), 𝛼(𝑡) varies from 0 to 1. 
2.2.2.6 Improved kinetic model 
An improved kinetics model was developed in a previous study[55] to quantify the 
physical stability of each amorphous dispersion system. [63]  All the experimental data were fitted 
into the improved Avrami equation using a multivariate nonlinear regression method to get the 
optimized parameters (k values and⁡𝛥𝐸𝐴) by MatLab software (version R2011b, MathWorks 
Inc.). 
𝛼(𝑡) = 1 −
1
1+𝑘𝑡𝑛
⁡⁡                                          (Equation 5) 
𝑘 = 𝑘0𝑒𝑥𝑝 (−
𝛥𝐸𝐴
𝑅𝑇
)                                        (Equation 6)[55], [64] 
Where n represents the dimensionality of crystal growth and k is the recrystallization rate 
constant, which can be expressed as Equation 6 where 𝑘0 describes the pre-exponential factor, 
𝛥𝐸𝐴 is activation energy, R is the universal gas constant and T is the absolute temperature (in 
kelvin). 
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2.3 Results and discussion 
2.3.3.1 Preparation of solid dispersions utilizing hot-melt extrusion 
All three grades of KlucelTM HPC with fenofibrate showed excellent extrudability under 
the utilized processing parameters. The TGA figure indicated both API and polymer were stable 
in the extrusion temperature range (Figure 2-1). Higher molecular weight grades of KlucelTM (LF 
and EF) required higher extrusion temperatures to decrease the torque on the extruder. Polymers 
with higher molecular weights usually have a higher glass transition temperature, which requires 
higher energy input to soften the polymer.[65] Milling of the extrudates was difficult due to the 
polymer’s high degree of thermoplasticity. Cryomilling, keeping the extrudate in -80℃  for 
several hours before milling, was utilized to resolve this issue.     
 
Figure 2-1. TGA figure for fenofibrate and Klucel ELF. 
 
Currently, many different polymers are used for hot-melt extrusion processing, and for a 
certain type of polymer, there might be multiple grades with different molecular weights or 
different substitution ratios (e.g. PVP, PEG, etc). The improved Avrami equation could be a 
powerful screening tool to arrive at the most suitable polymer for hot-melt extrusion processing. 
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The same evaluation process should be applicable to determine the effects of other excipients in 
a given formulation. 
2.3.3.2 HPLC analysis   
HPLC analysis of the freshly extruded solid dispersions showed no reduction of drug 
content nor was the appearance of a degradation peak from fenofibrate observed, which indicated 
that the extrudates were very stable during the processing conditions. All of the extrudates were 
well within the specifications (85~115%) of content uniformity standards. The results obtained 
in this study showed that the hot-melt extrusion process with Klucel™ and fenofibrate could 
have very high homogeneity regardless of the molecular weight of HPC used. 
2.3.3.3 Physical stability of solid dispersions determined by DSC  
The freshly extruded samples were tested by DSC and the absence of melting peaks 
indicated that the solid dispersion were in the amorphous state as shown in Figure 2-2 (red curve). 
As the stress test was conducted, the API in the dispersions transformed back into its crystalline 
phase, which was indicated by the increasing integration values of the melting peaks as shown in 
Figure 2-2 (purple curve). The peak area on the DSC thermogram is the ∆𝐻(𝑡), which is the 
melting enthalpies of the recrystallized solid dispersion sample. The peak area of physical 
mixture thermogram indicates the ∆𝐻(𝑃.𝑀. ), which represents the melting enthalpies of the 
physical mixture of the API and polymer. The ratio of these peak areas can be used to evaluate 
how much amorphous API recrystallized.[66] In the early stage of recrystallization processing, 
different formulations had significant different ∆𝐻(𝑡) which indicated different relative 
crystalinity. This phenomenon might due to the specific recrystallization activation energy of 
each formulation that caused different nucleation energy barrier for the API molecular. While in 
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the late stage of recrystallization processing, nucleation rate decreased as the portion of 
amorphous API decreased, the crystal growth rate turned into the governing factor.24 
 
Figure 2-2. Evaluation of crystallinity using DSC: pure fenofibrate (blue curve), physical mixture 
of 20%fenofibrate with Klucel LF (green curve), recrystallized solid dispersion (purple curve), 
amorphous solid dispersion (red curve). 
2.3.3.4 Assessment of the improved kinetic model 
The recrystallization predictions based on the original Avrami model and the new 
improved kinetic model is shown in Figure 2-3. The experimental data were fitted into the new 
modeling equation by a multivariate nonlinear regression method using MatLab software. Initial 
values of k = 0.1 were given to compute the optimized values of model parameters by 
minimizing the sum of residual squares using a successive linear programming method. 
Correlation coefficient, r2, for improved Avrami equation is 0.986, while r2 for the Avrami 
equation is 0.971, which suggests that the improved model provides a better fit than the Avrami 
equation. However, this is especially true in the late stages of recrystallization (after 50 hours). 
This is attributed to the changing of the nucleation rate in the improved Avrami equation,which 
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is decreasing with the decline of amorphous content in the system. The Avrami exponent n 
describs dimensionality of crystal growth in the solid dispersion, when n equals to 2, 3, 4, 
indicate, respectively, the rod, plate, spherical geometry for nucleation. For this study and most 
situations for small molecular API, n euqals to 3. 
 
 
 
Figure 2-3. Comparison of Avrami equation (r2=0.971) and Improved Avrami equation (r2=0.986) 
on recrystallization prediction based on relative crystallinity a(t) plotted against time for 15% 
fenofibrate with 85% Klucel ELF under 60°C /10% RH stability condition. 
 
2.3.3.5 The effect of polymeric carrier on amorphous solid dispersions stability  
Three different formulations of fenofibrate and Klucel™ ELF were prepared with 
different drug loadings of 10, 15, and 20%.  The experimental data showed a significant decrease 
in the recrystallization rate (k) with an increase in polymer content. With lower drug loading, the 
density of API in the polymeric matrix is lower, and the change in nucleation, along with the 
amount of molecules to nucleate in later stages, are both lower. Two formulations of fenofibrate 
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with Klucel™ LF and EF, respectively, were produced at a fixed drug loading of 10%. For the 
different grades of HPC (Klucel™ LF/EF/ELF), under the same drug loading and same stress 
test condition (60℃ /10%RH), LF exhibited a better recrystallization inhibitory effect than was 
observed for EF and ELF (LF>EF>ELF) (Table 2-2).  
Table 2-2. Recrystallization prediction results by the improved Avrami equation for fenofibrate 
amorphous solid dispersion with different grades of KlucelTM HPC under storage condition of 
60℃ /10%RH. 
Content of 
Fenofibrate (%) 
Polymer Carrier 
∆𝑯∞
∆𝑯(𝑷.𝑴. )
 
Final time 
(Hours) 
k 
(10-6) 
Content (%) Grade 
10 90 LF 61.1% ~168 8.24 
10 90 EF 67.7% ~144 14.5 
10 90 ELF 73.3% ~144 16.7 
 
Concerning the recrystallization rate constant (k) values, ELF>EF>LF. These data 
indicated that under the specified conditions, the API in ELF recrystallized faster than that with 
EF, or LF. The data also revealed from the ratio between⁡∆𝐻∞⁡𝑎𝑛𝑑⁡∆𝐻(𝑃.𝑀. ), that more API 
was remaining in the amorphous phase in the API/LF system. This difference might due to the 
difference of molecular weight between these three grades of HPC (Table 2-3). Klucel™ LF is a 
higher molecular weight polymer compared to EF and ELF. Klucel™ ELF, with the lowest 
molecular weight, possesses comparatively lower viscosity due to smaller chains, which could 
not provide the same energy barrier as EL or LF to prevent the recrystallization of the API. The 
polymer with the higher molecular weight could have a higher Tg [67],[68] which is a commonly 
accepted indication of physical stability improvement of amorphous solid dispersions.  
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Table 2-3. Molecular weight of Klucel™ LF/EF/ELF 
Polymer Klucel™ LF Klucel™ EF Klucel™ ELF 
Molecular 
Weight(Da) 
90000      80000           45000 
To develop a stable, high quality amorphous solid dispersion system for one API, the best 
polymeric carrier can be chosen by calculating the solubility parameters,[69] miscibility[70] and 
molecular interactions.[71] However, final physical and chemical stability assessment of a 
formulation is confirmed by long-term stability testing according to ICH regulations. The 
improved Avrami equation could be an accurate tool to evaluate the physical stability of various 
formulations within an abbreviated interval, thus saving valuable research and development time.   
 
Figure 2-4. Relative crystallinity a(t) plotted against time for formulations with different polymer 
content (90, 85 and 80% of Klucel ELF) under 60 °C /10%RH stability condition. 
 
2.3.3.6 The effect of temperature on the recrystallization rate constant 
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The samples were stored in stability chambers with fixed RH and three different 
temperatures (10%RH and 40, 50, 60℃). The selected storage temperatures were higher than 
those normally used for pharmaceutical stability testing in order to promote rapid 
recrystallization within a short time according to the ICH 2AQR guidance for stability testing. 
Under all of these conditions the characteristic S-shaped curve was noted again, which was 
observed in “Assessment of the improved kinetic model”, with faster recrystallization at 
increasing temperatures (Figure 2-5).  
 
 
Figure 2-5. Relative crystallinity a(t) plotted against time for 10% fenofibrate with 90% Klucel 
ELF under different temperature conditions (40, 50 and 60 °C /10%RH). 
 
The semi-log plot of k vs 1/T reveals that the crystallization rate constant increased 
exponentially with temperature within the temperature range studied (Figure 2-6). According to 
 𝑘 = 𝑘0𝑒𝑥𝑝 (−
𝛥𝐸𝐴
𝑅𝑇
) (Eq. 4), the recrystallization activation energy was determined by the slope 
of the linear regression of the lnk and 1/T since 𝑘0⁡𝑎𝑛𝑑⁡𝑅 are both constant. The formulation 
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with a greater slope indicates that the system has lower activation energy and could have faster 
recrystallization rate. Based on the value of the activation energy, the equation allows the 
prediction of recrystallization kinetics at temperatures outside the experimental range.  
 
Figure 2-6. An Arrhenius plot of recrystallization constant against temperature for 10% 
fenofibrate with 90% Klucel ELF under different temperature conditions 40, 50 and 60 °C 
/10%RH. 
 
Some samples stored in high temperature/low RH conditions (60℃ /10%RH) deliquesced 
in the late stages of the experiments. This event is due to the fact that the high temperature could 
decrease the critical RH for deliquescing by enhancing water uptake rate whereby the samples 
could reach the equilibrium weight gain more quickly.[72] Consequently, the higher moisture 
content of the system and increased molecular mobility triggered more recrystallization of API.  
2.3.3.7 The effect of relative humidity on the recrystallization rate constant 
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Initial amorphous solid dispersions samples were stored in the stability chambers with 
fixed temperature and three different RH (60℃  and 10, 40, 70%RH) to determine the influence 
of humidity on the recrystallization process. Rapid recrystallization rates were observed under 
high RH (Figure 2-7). 
 
Figure 2-7. Relative crystallinity a(t) plotted against time for 10% fenofibrate with 90% Klucel 
ELF under different RH conditions (10, 40 and 70%RH/60°C). 
 
Linear regression of the experimental data (Figure 2-8) suggests that k increases linearly 
rather than exponentially over the range of RH studied, which confirmed Yang’s results for PVP-
efavirenz solid dispersion systems.[55] Different polymer-API combinations would have 
regression equations with different sloped and the slopes could be a quantitative factor to 
evaluate how sensitive the system is to the RH condition. On the other hand, the Y-intercept of 
the regression equation could serve as an indicator to quantify the other factors’ contribution to 
the recrystallization rate under 0% RH, such as polymer and temperature. Moisture potentially 
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acted as a plasticizer and hence lowered the glass transition temperature of the solid dispersion 
system, which increased the recrystallization rate constant.[73] The rapid recrystallization might 
also be due to the increased molecular mobility of APIs in the systems caused by high RH which 
can increase the molecular rotation and movement subsequently to a lower glass transition 
temperature of the dispersion system.[74] Since the recrystallization rate constant has a liner 
relationship with the RH, we can assume that the moisture content of the solid dispersion system, 
which is determined by the polymer’s hydroscopic nature, is proportional to the recrystallization 
rate of the API during stability testing. This indicates that characterizing the water uptake ability 
of the polymer carrier and other excipients is very important when developing a solid dispersion 
system.  
 
Figure 2-8. Recrystallization rate constant plotted against RH for 10% fenofibrate with 90% 
Klucel ELF under different RH conditions (10, 40 and 70%RH/60 °C). 
 
The deliquescence phenomenon was also observed under high RH conditions. Study of 
the consequence of deliquescence on amorphous solid dispersion samples and hygroscopicity of 
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polymer carriers will be helpful in developing solid dispersion system with better physical 
stability. Surface properties (e.g. surface free energy, surface area, etc.), water uptake ability and 
mechanisms of the polymer carrier,[75] might be the causes of different recrystallization 
inhibition abilities for the amorphous solid dispersion system under the same RH conditions, 
which will be the focus of our future studies.   
2.4 Conclusion 
The improved Avrami equation demonstrated more accurate evaluation for all of the solid 
dispersion systems investigated in this study. This is particularly evident for the late stages of the 
recrystallization process, which provides a novel approach for early stage formulation 
development of amorphous solid dispersion systems. This can be viewed as both time and cost 
effective when compared to the conventional ICH stability tests. By resolving the relationships 
between the recrystallization rate constant, temperature, relative humidity and formulation, an 
accurate and reliable prediction can be obtained in reference to recrystallization kinetics. The 
polymers (Klucel™ EF/LF/ELF) inhibited the recrystallization process of the amorphous API 
and HPC grades with a higher molecular weight exhibited more favorable results. The method 
utilized in this study would also be useful for screening the most suitable polymeric carrier and 
other excipients in solid dispersion systems. 
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CHAPTER 3 
THE EFFECTS OF POLYMER CARRIER, HOT MELT EXTRUSION PROCESS AND 
DOWNSTREAM PROCESSING PARAMETERS ON THE MOISTURE SORPTION 
PROPERTIES OF AMORPHOUS SOLID DISPERSIONS 
 
3.1 Introduction 
There are many technologies currently used to prepare solid dispersion systems, which 
include solvent casting, spray drying, and hot melt extrusion [76-78]. It is argued by many, 
among all of these techniques that hot melt extrusion (HME) [79], or melt extrusion, is the most 
promising techniques, which include, advantages such as continuous processing, easy to scale up, 
solvent free fabrication and lower production costs [80-84].   
For most of the HME formulations, polymer carriers entail a large proportion of all of the 
components, which performs the role of recrystallization inhibitor, as well as that of the 
dissolution controller [85, 86]. However, at the same time, most commonly used polymers in 
HME processing are hydrophilic polymers or hygroscopic materials. Most amorphous solid 
dispersion systems containing only the API and polymer carrier, are difficult to be stabilized 
under the environmental conditions with moisture and temperature near the glass transition 
temperature (Tg). Moreover, the polymer carriers are hygroscopic in nature and this could 
aggravate the influence of moisture by lowering the systems Tg, which consequently increases 
molecular mobility and facilitates the recrystallization of the API.  
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Evaluation of drug-polymer solubility and miscibility, and the effect of polymer type on 
the stabilization of amorphous APIs have been reported [86-88]. However, once exposed to 
moisture, the drug-polymer binary system will alter to a drug-polymer-water ternary system.  
In order to investigate the moisture induced changes in the solid dispersion, utilizing 
FTIR spectroscopy in the analysis provides several advantages [89]. Sensitive and non-invasive 
characterization of drug-polymer interactions can be performed quickly, even with the controlled 
sample temperature and atmosphere. Moreover, FTIR chemical imaging provides 
straightforward information of miscibility or mixing of the drug and polymer [90, 91]. However, 
the effect of moisture on the drug dispersion homogeneity is still limited by using this visualized 
technology.  
Previous research has been conducted to investigate the influence of moisture on the 
formulations containing hygroscopic polymers [92-94]. However, evidence is still deficient as to 
how polymer properties, HME processing and downstream processing, affects moisture uptake 
within the systems. In order to achieve a good commercial solid dispersion product, thoroughly 
understanding the effect of formulation as well as the preparation technology is paramount. It is 
well recognized that different processing technologies could impart huge differences on the 
physical properties of solid dispersions [95-98]. However, research on how preparation 
techniques and downstream processing affects the solid dispersion is still very limited. 
Therefore, the objective of the present study was to investigate the effects of polymeric 
carrier, HME processing and other downstream processing parameters on the moisture sorption 
properties of amorphous solid dispersions. Polyethylene glycol (PEG), Hydroxypropyl cellulose 
(HPC) and Ethyl cellulose (EC) were chosen as polymer carriers and fenofibrate (FF) was used 
as a model drug. The moisture sorption/desorption isotherms were measured for various 
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molecular weight (MW) grades of the polymer carrier, physical mixture (PM) of polymer and 
drug, and amorphous solid dispersions prepared by HME technology. To the best of the authors’ 
knowledge, this is the first study compared the moisture uptake ability of melt extruded 
amorphous solid dispersion with different hygroscopic nature polymer carriers and different 
molecular weight. Also the effects of hot melt extrusion processing and downstream processing 
on the moisture sorption ability of solid dispersions were investigated for first time. 
3.2 Materials and methods 
3.2.1 Materials 
Hydroxypropylcellulose (Klucel™ HPC; grades LF/EF/ELF) and Ethylcellulose 
(Aqualon® EC; grades N7/N14/N22) were kindly donated by ASHLAND Specialty Products 
(Wayne, NJ, USA). Polyethylene glycol (3350, 4000, and 6000) were purchased from Sigma–
Aldrich (St. Louis, MO, USA). And fenofibrate was purchased from Aurobindo Pharma Ltd. 
(Hyderabad, India). Reagent grade methanol was purchased from Sigma–Aldrich (St. Louis, MO, 
USA). All the other reagents used in this study were of the analytical grade. 
3.2.2 Methods 
3.2.2.1 Preparation of amorphous solid dispersions using hot-melt extrusion 
Amorphous solid dispersions of fenofibrate and model polymer with various MWs were 
prepared using HME technology. Thermal gravimetric analysis (TGA) and differential scanning 
calorimetry (DSC) were utilized to determine the extrusion processing temperature range. The 
API and polymer were mixed in a V-cone blender (MaxiBlendTM, GlobePharma) at 30 rpm for 
10 min and then extruded with a co-rotating twin-screw extruder (Process 11, ThermoFisher 
Scientific) into uniform rod extrudates, at an extrusion processing temperature range based on 
the formulation composition and a screw speed of 100 rpm. The maximum feed rate utilized was 
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10 g/min, in order to maintain the torque (%) indicator of the extruder within a safe mode range. 
The extrudates were milled using a comminuting Fitz Mill (Model#L1A, Fitzpatrick Company, 
IL) at a rotor speed of 3600 rpm.  
3.2.2.2 Dynamic vapor sorption (DVS) 
The water sorption behavior of API, physical mixture, milled extrudates, and compressed 
milled extrudates were determined by Intrinsic DVS (Surface measurement systems, London, 
UK). 20±0.5 mg samples were exposed to the controlled relative humidity profile (0– 90 – 0% in 
10% steps) at a constant temperature (25°C), and the weight changes were measured by a 
CahnD200 ultra-microbalance (±0.01mg mass resolution). The dm/dt mode was used in all the 
steps, and the limitation was set at 0.001%/min to detect the equilibrium (the instrument would 
start next step when the samples dm/dt value equal or less than 0.001%/min). At first step, 
sample was dried at 0%RH, and the equilibrated mass at 0%RH was used as reference mass. The 
water sorption isotherms were calculated using the equilibrated sample mass from each step [99]. 
3.2.2.3 Thermal gravimetric analysis (TGA) 
TGA studies were performed on Perkin Elmer Pyris 1 TGA with the PyrisTM software 
(PerkinElmer Life and analytical sciences, CT, USA). 3-5 mg of the sample was weighed and 
heated from 20 °C to 300 °C under an inert nitrogen atmosphere at a flow rate of 20 °C/min. 
Percent weight loss was plotted against temperature to determine the weight loss. The TGA 
sample of fenofibrate was holding at the highest extrusion temperature (145 °C) for 15 min to 
test the thermal stability. 
3.2.2.4 Differential scanning calorimetry (DSC) 
DSC (Perkin Elmer, Diamond DSC) was utilized to measure the melting enthalpy of the 
solid dispersions. Samples were weighed (3-5 mg) in an aluminum sample pan and hermetically 
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sealed at each time point using a heating rate of 20°C/min from 30°C to 200°C under an inert 
nitrogen atmosphere at a flow rate was 20 mL/min. An empty pan was used as reference. 
Measurements were repeated three times. An Indium standard was used for calibration. 
3.2.2.5 HPLC-UV Analysis  
A Waters HPLC-UV system (Waters Corp, Milford, MA), equipped with a Luna 5um C18 
100Å  column (Phenomenex, US), was used to detect fenofibrate at a wavelength of 286 nm. The 
mobile phase consisted of acetonitrile and phosphoric acid in water (pH=2.5) at a ratio of 85:15 
(v/v). The flow rate was maintained at 1.0 mL/min. The injection volume was 20 μL. The 
observed retention time of fenofibrate was 6 min. The data was acquired and processed using 
Waters Empower 3 software suite. 
3.2.2.6 Scanning electron microscopy (SEM) 
SEM was used to study surface morphology of the solid dispersions.  Samples were 
mounted on aluminum stubs held with a carbon adhesive film. Gold was used to coat the 
Samples by a Hummer® 6.2 sputtering system (Anatech LTD, VA, USA) in a high vacuum 
evaporator. The surface topography of the sample was analyzed by a scanning electron 
microscope operating at an accelerating voltage from 1.0 kV to 5.0 kV (JEOL JSM-5600).  
3.2.2.7 FTIR and Chemical Imaging 
Infrared spectra were collected on an FTIR bench (Agilent Technologies Cary 660) fitted 
with a MIRacle ATR (Pike Technologies) sampling accessory in the spectral range of 4000-650 
cm-1. The bench ATR was equipped with a single bounce diamond coated ZnSe internal 
reflection element. Chemical images were collected using an infrared microscope (Agilent 
Technologies Cary 620 IR), which was equipped with a 64 x 64 focal plane array (FPA) detector. 
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The images were collected with a germanium micro ATR sampling accessory giving a field of 
view (FOV) of approximately 70 x 70 microns with 1.1µm spatial resolution.  
3.2.2.8 Statistical Analysis 
All statistical analysis was calculated using SPSS v.18.0 (IBM Corp., Armonk, NY, 
USA). To compare the differences of moisture sorption between solid dispersions with different 
polymers, one-way ANOVA followed by t-test was used for continuous variables. All significant 
tests were two-tailed and p<0.05 was considered significant. 
3.3 Results and discussion 
3.3.1 Preparation of amorphous solid dispersions utilizing hot-melt extrusion 
The TGA study results confirmed that all of the polymers and the model drug were stable 
at the temperature range of 30-200°C, as no degradation peaks were observed (Figure 3-1). The 
TGA sample of model drug was holding at 145 °C for 15 min, and the weight change was less 
than 0.5% which indicated the thermal stability of fenofibrate since the holding time was much 
longer than retention time in the extruder(less than 5 min).  All grades of model polymer with the 
model drug fenofibrate showed excellent extrudability under the utilized processing parameters 
(Table 3-1). Formulations containing higher MW grades of model polymers required higher 
extrusion temperatures to decrease the torque on the extruder, and pure polymers without 
fenofibrate needed even higher temperatures for processing. Polymers with higher MW usually 
have a higher Tg, which requires higher energy input to soften the polymer [65]. However, 
fenofibrate with a Tg of -20°C could lower the systems Tg by acting as a plasticizer [100]. The 
extrudates of HPC were difficult to mill due to the polymers high degree of thermoplasticity. 
Cryomilling, keeping the extrudate in -80°C for several hours before milling, was utilized to 
resolve this issue. All physical mixture and milled extrudates were passed through the same 
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number sieve to ensure the same particle size. From Figure 3-2, DSC data confirmed that all of 
the extruded formulations with the drug were amorphous solid dispersions (PXRD also 
corroborated the DSC findings, data not shown). HPLC analysis of the freshly extruded solid 
dispersions showed no reduction in the drug content nor demonstrated a degradation peak from 
fenofibrate, which indicated that the extrudates were very stable during the processing conditions. 
All of the extrudates’ content uniformities were well within the range of 85-115%. 
 
Figure 3-1. Thermal gravimetric analysis results for all polymer carriers and the model drug 
(polyethylene glycol, ethyl cellulose and hydroxypropylcellulose) did not show any degradation, 
so the three lines overlapped). 
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Figure 3-2. Differential scanning calorimetry result for pure model drug and hot melt extruded 
amorphous solid dispersions. Red line: fenofibrate; blue line: PEG 3350 with 10% fenofibrate; 
green line: HPC ELF with 10% fenofibrate; orange line: EC N7 with 10% fenofibrate. 
 
Table 3-1. Composition of solid dispersions and hot melt extrusion parameters for each 
formulation. (For all formulations containing PEG, the last 3 zones temperature were set at 30 ̊C 
to avoid liquid extrudate.) 
 
Polymer Carrier Drug 
Content 
(%) 
Temp.( ̊C) 
Screw 
Speed 
(rpm) 
Torque 
(%) 
Type 
Content 
(%) 
Molecular 
weight 
HPC 
LF 95000 10 130 100 35-50 
EF 80000 10 125 100 35-45 
ELF 40000 10 125 100 35-40 
EC 
N7 65000 10 140 100 35-45 
N14 120000 10 145 100 35-50 
N22 140000 10 145 100 40-50 
PEG 
3350 3350 10 75 100 10-20 
4000 4000 10 80 100 10-20 
6000 6000 10 80 100 10-20 
 
3.3.2 Effect of Polymer carrier on the moisture sorption of solid dispersions 
For the same model drug, fenofibrate, three different polymers HPC, EC and PEG 
corresponding to hygroscopic amorphous, hydrophobic amorphous, and hygroscopic semi-
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crystalline polymer, respectively, were selected to prepare the solid dispersions for testing 
(Figure 3-3, 3-4 and 3-5). To clarify the comparisons, all of the important parameters are 
summarized in Table 3-2. 
 
Figure 3-3. Dynamic vapour sorption measurements of EC N14–FF amorphous solid dispersions 
prepared by hot melt extrusion (n = 1): (a) change in mass plot and (b) isotherm plot. 
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Figure 3-4. Dynamic vapour sorption measurements of HPC EF–FF amorphous solid dispersions 
prepared by hot melt extrusion (n = 1): (a) change in mass plot and (b) isotherm plot. 
 33 
 
 
Figure 3-5. Dynamic vapour sorption measurements of PEG 4000–FF amorphous solid 
dispersions prepared by hot melt extrusion (n = 1): (a) change in mass plot and (b) isotherm plot. 
 
At the 90% RH condition, the pure drug fenofibrate only had a weight change of 0.125%. 
This would indicate that even at high RH conditions the API absorbs very little water from the 
moist air. According to the isotherm hysteresis, after desorption processing, the weight change 
approached 0%, which would suggest that the API had very low ability to hold the moisture. 
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In the case of the hydrophobic polymer carrier, the EC-FF solid dispersion system 
showed similar water uptake properties as the pure drug. The low water solubility nature of EC 
makes it a perfect polymer candidate for sustained and controlled release formulations[92]. 
Although, EC is considered as water insoluble, the polymer still can sorb some moisture by the 
mechanism of hydrogen bonding, which was led due to the polarity difference between the 
oxygen atom and the ethyl group in the ethoxy group [101]. 
However, the controlled release formulation is only a small part of all drug products. To 
achieve other dissolution profiles or release mechanisms, water soluble polymer carriers are 
applicable to be incorporated into a formulation. Indeed, even for the same dissolution type, 
different dosage forms might require other polymer with special physicochemical properties, 
such as HPC and PEG for HME extruded films [83, 102].  
The hygroscopic characteristic of polymers depend on its structure, hence the water 
uptake ability for both PEG and HPC polymers depends on either oxygen atoms or hydroxyl –
OH groups, which may contribute greatly to the high water solubility by forming hydrogen 
bonding with water [103]. 
Both PEG and HPC exhibited high moisture sorption properties, however due to their 
hygroscopic nature, these two polymers had significantly different sorption isotherm curves. 
HPC begins water uptake from the environment at low RH conditions, and with the increase in 
the RH there was an increase in the % weight change. Conversely, PEG did not take up much 
moisture until the RH exceeded a specific point. This phenomenon was caused by the 
hydrophilic nature of the polymer and due to the commencement of deliquescence [104]. For 
both amorphous and semi-crystalline polymers with a hygroscopic nature, after the exposure to 
high moisture environment, the physical properties are altered by the sorbed moisture, coupled 
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with the visible change such as caking and finally transforming into a semi-liquid state. Previous 
studies have shown that for semi-crystalline polymers like PEG, the phenomenon of 
deliquescence would happen once the atmospheric RH exceeds a critical relative humidity RH0 
[105, 106]. 
3.3.3 Effect of Polymer Molecular Weight on the moisture sorption of solid dispersions 
For all of the polymers (EC, PEG and HPC) used in this study, three different grades of 
various MW were used in the ASD formulations to investigate how MW affects the moisture 
sorption properties of the solid dispersion systems. Statistical analysis showed that maximum 
weight changing % for the HPC group and PEG group demonstrated significant differences 
(p<0.05), whereas no significant difference was observed for EC group (p>0.05). ASD 
containing different grades of EC revealed very low maximum weight changes % and no 
significant difference in between N7/N14/N22 was observed, which is most likely due to the 
hydrophobic nature of the polymer (Table 3-2). 
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Table 3-2. Important parameters summarized from vapor sorption isotherms of amorphous solid 
dispersion samples. (Meant ± SD, n=3) 
 
Polymer Carrier Maximum 
Weight 
Changing (%) 
Weight 
Changing at 
60%RH (%) 
Hysteresis at 
0% RH  
(%) 
 Grade Molecular 
Weight 
HPC ELF 40000 22.81±0.19 8.21±0.23 1.83±0.16 
EF 80000 20.81±0.17 8.96±0.21 1.93±0.23 
LF 95000 19.23±0.17 6.29±0.17 0.99±0.05 
EC N7 65000 3.42±0.04 1.70±0.07 0.00 
N14 120000 3.15±0.08 1.49±0.05 0.00 
N22 140000 3.10±0.04 1.45±0.03 0.00 
PEG 3350 3350 29.30±0.14 0.49±0.10 3.69±0.19 
4000 4000 25.20±0.44 0.44±0.03 2.53±0.18 
6000 6000 23.26±0.27 0.39±0.03 2.30±0.15 
 
HPC LF exhibited a lesser amount of water sorption as compared to the other grades of 
HPC with lower MW (LF<EF<ELF). PEG also demonstrated similar MW related sorption 
properties. However besides these findings, key changes were observed. Each MW of PEG 
displayed an abrupt increase in weight change when the step RH arrived at one certain point. As 
stated earlier, this should be the critical RH0 for the semi-crystalline polymer. When the vapor 
pressure was lower than the critical vapor pressure of the saturated aqueous solution of the PEG, 
a very small amount of water could be captured by the polymer via surface hydrogen bonding; 
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when it surpassed the RH0, the phase transformation would commence, directing the sample into 
a semi-solid state. Since at this stage, the aqueous solution is thermodynamically more stable 
than the semi-crystalline phase, the dissolution of the solid dispersion and water sorption 
continued until this ternary system arrived at a thermodynamic equilibrium state. As the critical 
RH was concentrated in the range of 70-90%, the DVS method for PEG was changed by 5% in 
each step in this range and the critical RH increased as the MW of PEG in the solid dispersion 
increased. Since the deliquescence process was temperature and RH dependent, the weight 
change may increase significantly if the formulation is stored at high RH for a longer period of 
time.  
Although this deliquescence and critical RH had been investigated for several small 
molecules, there are very limited studies for crystalline polymers reported in the literature. 
Generally speaking, a higher MW polymer always possesses longer polymer chains, which may 
decrease the mixing entropy of the polymer and water, hence lowering the aqueous solubility of 
the polymer. At the same time, lower MW polymers tend to be more hydrophilic due to the 
higher relative fraction of hydroxyl groups. The effect of MW could be limited if increasing MW 
could not change the fraction of hydrophilic groups.  
At the same time, the all the polymer used in this study, the polymer with higher MW 
exhibit higher viscosity. Once the moisture saturated the surface of the solid dispersion sample, 
polymer-water mixture would form with different viscosity. And the polymer with higher MW 
and viscosity would slow the late stage of moisture absorption comparing with the same kind of 
polymer with lower MW. With the higher viscosity, longer equilibrium time might be needed 
since the molecular mobility and phase transaction would be slower. This higher viscosity caused 
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by higher MW might be another factor caused the less hygroscopic of the solid dispersion 
samples with higher MW polymer carrier.   
3.3.4 FTIR Analysis and Chemical Imaging  
Compared with DVS data, FTIR spectrums provided more detailed information of the 
solid dispersion systems at the molecular level. Figure 3-6 illustrates a detailed perspective of 
how the peak positions and intensity vary with HPC molecular weight after exposure to 90% RH 
for 24 hours. 
 
Figure 3-6. FTIR spectrum of HPC fenofibrate solid dispersion after storing at 25°C/90%RH for 
12 h. Blue line: HPC ELF with 10% fenofibrate; black line: HPC EF with 10% fenofibrate; red 
line: HPC LF with 10% fenofibrate; and purple line: HPC ELF with 10% fenofibrate before 
exposed to RH. 
FTIR imaging (Figure 3-7) indicated that the API was homogeneously dispersed within 
the freshly prepared amorphous solid dispersion, however the homogeneity was changed after 
storage at the high RH condition (25 °C/90% RH). With regard to API homogeneity as 
illustrated in the chemical images, considering the relatively small field of view (70 x 70 microns) 
and the marked intensity of absorbance resulting from fenofibrate’s characteristic and spectrally 
resolved carbonyl centered at 1723cm-1, the API is homogenously dispersed in the fresh 
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extrudates (Figure 3-7A; time point 0). The additional accumulation of adsorbed water, resulting 
from continued exposure to the relative humidity, produced areas of migrated fenofibrate. In the 
chemical images (Figures 3-7 A-D), this is graphically illustrated by the growing intensities of 
both fenofibrate pockets, represented by the colour orange and red, and the voids where it is 
increasingly missing, represented by the colour blue.  
As stated previously, the polymers’ hygroscopic nature attributed to sorption of moisture. 
This may result in many implications such as accelerating degradation by providing a reactant or 
reaction medium, and also negatively affecting the physical stability of the ASD by increasing 
molecular mobility and promoting recrystallization [107-109]. As the molecular mobility 
increases and the miscibility decreases driven by moisture, the drug-rich and polymer-rich 
amorphous domains could be potentially formed, prior to complete phase separation and drug 
recrystallization [110]. The uneven distribution of yellow color peaks, as shown in Figure 3-7, 
could be evidence of amorphous-amorphous phase separation.  
 
Figure 3-7. FTIR chemical imaging of HPC LF amorphous solid dispersions after storing at 
25°C/60% RH for (a) 0, (b) 2, (c) 3 and (d) 4 weeks. 
3.3.5 Influence of Hot Melt Extrusion processing  
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Polymer carriers, APIs, and other additives normally comprised the solid dispersion 
systems. All of these components and their respective interactions determine the characteristics 
of the system. However even for the same formulation, if prepared by different technologies, the 
physicochemical properties could be changed significantly. The moisture sorption of polymer 
and polymeric solid dispersions have been documented in some studies, Konno found that the 
polymer in solid dispersion system could increase the moisture content of the system comparing 
to that of the pure amorphous drug part [111]. Rumondor stated that solid dispersion with 
different polymer carrier could go under phase separation at different RH conditions mainly 
effected by the molecular interaction between API and polymer carrier [112].To date, no study 
has reported how processing such as HME affects the water sorption/desorption of amorphous 
polymeric solid dispersion systems.  
The kinetics of water uptake for each physical mixture (P.M.) and corresponding milled 
HME extrudates were measured at 25 °C by DVS and all of the important parameters are 
summarized in Table 3-3.   
Table 3-3 Important parameters summarized from vapor sorption isotherms and physical 
properties of amorphous solid dispersions (HME) and physical mixture (P.M.). (Mean ± SD, n=3) 
 
Drug Content 
10% 
Maximum Weight 
Changing 
(%) 
Density 
(g/cm3) 
Surface area 
(m2/g) 
HPC 
ELF 
HME 22.81±0.19 0.43±0.03 0.358±0.02 
P.M. 24.2±0.17 0.38±0.01 0.441±0.02 
EC  
N7 
HME 3.42±0.04 0.33±0.01 0.298±0.03 
P.M. 3.53±0.06 0.31±0.03 0.301±0.04 
PEG 
3350 
HME 29.30±0.14 1.17±0.04 1.162±0.13 
P.M. 29.98±0.07 1.06±0.03 1.217±0.08 
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The comparison of the sorption isotherms of the physical mixture and milled HME 
extrudates demonstrated that HME processing could significantly change the maximum moisture 
sorption of the samples with HPC-FF, EC-FF and PEG-FF (p<0.05). The maximum weight 
changing % difference was not that much between EC-FF HME and PM.  The moisture sorption 
ability of the EC-FF PM system was already very low (approximately 3%) that the effect of 
HME processing was limited. 
The maximum weight change was always attained at the highest RH, or so called water 
activity, which was the most important indicator for the potential sorption of moisture by the 
formulation. The entire sorption isotherm was a process in which the moisture mixed with the 
solid dispersion by physical adsorption, chemisorption and multilayer condensation was attained. 
When comparing the isotherms curves of all of the HPC-FF containing samples, an interesting 
phenomenon was observed. The physical mixture and HME formulations exhibited identical 
sorption behavior at an early stage, and the differences in weight change for all formulations 
were observed in the later stages (RH>60%). The properties of water absorbed in the later stages 
should be similar to those of the free water that was held in the large capillaries or voids. 
According to the relatively short desorption equilibrium time, the later stage water was loosely 
bonded to the solid dispersion surface, which indicates that the vaporization enthalpy should be 
almost the same as the pure water. From this point of view, the authors hypothesized that HME 
processing may change the volume of the crevices and the space of the large capillaries. To 
confirm this hypothesis, both physical mixture and HME formulations were characterized by 
SEM, density meter and surface area measurement (Figure 3-8). The physical mixture sample 
had rough surface and lots crevices were observed. And the HME sample exhibited smooth 
surface and dense structure.   
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Figure 3-8. Scanning electron microscopic images for the physical mixture and milled hot melt 
extrudates: (a and b) physical mixture of HPC ELF with 10% fenofibrate; (c and d) milled HME 
solid dispersion of the same formulation. 
 
 During the HME processing, the physical mixture was soften and melted under high 
temperature and high shear rate. All materials were reshaped by two key steps, first forcing 
through small round shape die and second milling into small size particles. By pushing the 
formulations through the die, density of the material could be increased, and no more small 
cavities could exist in the solid dispersion particles. And the high condensation polymer could 
have chains with less flexibility and less space to rotate which could lead to lower moisture 
uptake. The milling processing could only affect the surface of the solid dispersion particles, not 
the inside. Comparing with the raw material, milled extrudate tend to have smoother surface. The 
physical absorption of moisture could be lowered by the less surface area. At same time, the PM 
samples with higher surface area would provide more hydrogen bonding sites, so that more water 
could be uptake by chemisorption. As in the melt extruded solid dispersion, fenofibrate was 
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dispersed in the polymer matrix on molecular lever, the molecular interaction like hydrogen 
bonding between API and polymer could reduce the available hydrogen bonding sites for water 
which would lead to a slower moisture uptake, less weight change and less hygroscopicity of the 
system [113]. 
3.3.6 Effect of different Compression Force  
The hot melt extruded solid dispersion can be shaped into many different final dosage 
forms, such as pellets, films, and suppositories. However, the tablet is still the most popular 
dosage forms on the market, which means that a few additional downstream processing steps 
might be needed for the extrudates. In the downstream processing, compression force utilized in 
the tableting step might have a significant effect on the moisture sorption ability of the tablet. In 
order to eliminate the effects from other excipients, only milled extrudates were used to compact 
tablets(200mg) by different compression force (5, 10, 15, 20, 25 kN) using 8mm round flat 
tooling set with manual compaction machine. The HPC-LF-FF ASD system was chosen as a 
model system and the water content of the samples were measured under 25°C/90% RH for 48 
hours (n=3) (Figure 3-9). 
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Figure 3-9 Water content (weight changing) plot of tablets containing HPC LF–FF amorphous 
solid dispersions with different compression force under 25°C/90% RH for 48 h (mean ± 
standard deviation, n = 3). 
 
The statistical analysis showed the significant differences between 5, 10, 15 and 20kN 
force groups (p<0.05). However, the statistical analysis between the 20 and 25kN groups did not 
indicate a significant difference (p=0.43). Higher compression force can decrease the moisture 
sorption of the ASD tablet, but this effect arrived at a plateau after 15 kN (samples with 20 and 
25 kN compression force did not show any significant difference). Also, high compression force 
(20 and 25 kN) exhibited a sticking issue during the compression process and previous studies 
have shown that higher compression force might induce the immiscibility of drug and polymer 
by weakening and/or disruption of intermolecular hydrogen bonding [114]. 
The porosity of the compacts was measured to explain the effect of compression force. 
From low to high compression force groups, the compacts porosities were: 13.6±3.7%, 9.2±2.1%, 
7.2±1.3%, 6.3±0.9% and 6.5±1.7% (n=3), respectively. The porosity was decreased as the 
compression force increased. As the porosity decreasing, the surface to absorb the moisture 
would also decrease which could slow the water uptake process. At same time, less surface area 
could lead to less hydrogen bonding sites which could lower the hygroscopicity of the samples 
with higher compression force.  
3.4 Conclusion 
In this study, HPC-FF, EC-FF and PEG-FF amorphous solid dispersion systems were 
successfully prepared by HME technology. This is the first time that the moisture sorption 
abilities of amorphous solid dispersions prepared by hot melt extrusion technology with different 
 45 
 
polymeric carriers has been reported. Also, this study investigated the moisture sorption from 
both the formulation as well as processing approaches, which are very limited as reported in 
previous literature. The nature of the polymer, molecular weight of the polymer, HME process 
and downstream processing parameters were found to have a significant effect on the moisture 
sorption ability of the amorphous solid dispersion systems. As moisture plays an important role 
in the physical and chemical stability of the solid dispersion, it becomes imperative to understand 
the effect of both formulation and processing parameters that influence the moisture sorption 
properties of the solid dispersions. The data, and hence knowledge, attained within this study 
would be extremely valuable for future commercialization of drug products containing solid 
dispersions.   
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CHAPTER 4 
SCREENING OF AQUEOUS SUSPENSION STABILIZER FOR SPRAY DRIED 
AMORPHOUS SOLID DISPERSION 
 
4.1 Introduction 
Several technologies now are widely used to prepare amorphous solid dispersions, which 
include confined impinging jet method, hot melt extrusion and spray drying, etc. Among these 
methods, spray drying has its own advantages. Spray drying is capable of generating ASDs 
directly from solutions by fast drug/polymer solidification from rapid removal of organic solvent 
in the solutions by single step with a high efficiency. However, comparing with technology like 
hot melt extrusion, the yield rate for traditional spray drying is still very low. This will be an 
issue when the batch size is small and the amount of compound is limited. This makes it 
impractical for utilizing spray drying to formulate the water poorly soluble APIs during the drug 
discovery and early research stages. 
The Buchi B-90 nano spray dryer equipped with nozzles with different sizes vibrating 
meshes (4-7 µm) to control the spray droplets, also the advanced electrostatic particle collector to 
collect the spray dried particles. This model of spray dryer is able to produce ADSs with very 
small amount of spray volumes and keeps the particle size consistent. Li et al,. reported using 
this process to archive nanoparticles with high yield (70-90%) using 4 µm nozzle cap mesh. 
However the ASD particles produced by spray drying always have a small particle size 
which might cause some issues for the downstream processing and dosing to animals during the 
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toxicology studies. For the animal studies, spray dried particles can be formulated into mini-
tablets, mini-capsules and suspensions. Even with the small size, mini-tablets and mini-capsules 
are difficult to dose to animals like rats and beagle dogs. The suspension of spray dried particles 
turned into the first choice of dosage forms for the animal study, but the physical stability of the 
ASDs could play a vital role to affect the drug release and bioavailability.    
In toxicology studies, spray dried particles are usually formulated as suspensions and 
dosed to animals by oral gavage. When ASD containing pH-dependent polymers are used, the 
suspension can be maintained by adjusting the pH of the aqueous medium to acidic conditions in 
which the ASD is largely insoluble, so that minimum about of the drug could release before 
dosing to the animals. At same time, the ASD with enteric polymers should not undergo 
recrystallization before dosing and during present in the stomach. Also, though the spray dried 
particles might have consistent particle size distribution, after formulated into suspensions, 
aggregation and flocculation could hinder the dissolution and bioavailability of the ASDs. 
 Currently, formulations of ASD suspension is still mainly depends on empirical methods 
like high throughput screening to screen for a viable suspension formulation for a given solid 
dispersion system. Suspension formulations are further complicated by the presence of other 
stabilizers adding into the liquid medium to achieve a stable and functional suspension. 
Surfactants are often used to improve the wettability of the solid dispersion particles and 
maintain the rheological properties of the properties of the suspension. Polymers can be used to 
increase the viscosity of the liquid medium and keeping the particles suspended.  
In this project, we systematically studied the impact of commonly used surfactants and 
polymers on the stability of ASD suspensions using a Nikon polarized microscopy equipped with 
an automatic stage. Also, different combinations of polymer carrier and model drugs were used 
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in the study to investigate the general rules choosing the appropriate stabilizer for the aqueous 
suspension of ASD which can prevent the particle aggregation, ASD recrystallization and drug 
releasing during storage. 
 
Figure 4-1. Schematic of suspension preparation and PLM characterization of the samples. 
 
4.2 Materials and methods 
4.2.1 Materials 
HPMC-AS LF was purchased from Shin-Etsu (Shin-Etsu Chemical Co., Ltd Japan). 
Polyvinyl Acetate Phthalate (PVAP) was purchased from Colorcon (Harleysville, PA, USA). 
Indomethacin and Ketoconazole were purchased from Sigma-Aldrich (St. Louis, MO, USA). All 
other chemical reagents used in the study were of ACS and high grade purity. 
4.2.2 Methods 
4.2.2.1 Spray drying 
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All powders in the study were prepared via spray drying using the B-90 (BÜCHI 
Labortechnik AG, Flawil, Switzerland). A 1% w/v solution of polymer carrier in acetone was 
prepared by dissolving polymer in acetone and stirring overnight. The model drug was dissolving 
into the polymer solution to make polymer:drug ratio to 2:1(drug loading 33.3% w/w). All 
solutions were centrifuged at 3000 rpm for 15 min, and the supernatant was used for spray 
drying to minimize the nozzle blockage. For the spray-drying process, the flow rate was set as 2, 
a 7 µm mesh nozzle cap was used, and 100% of the feeding solution was sprayed. Air flow rate 
was 115L/min and inlet temperature were set as 75°C. The dried powder was collected from the 
particle collecting chamber using a scraper and dried in a vacuum chamber for 24 hours, then 
stored in refrigerator for further characterization. 
4.2.2.2 Preparation of suspension 
The 5 mg of spray dried particles were accurately weighted into a 10 ml glass vial and 4 
ml aqueous solution was added into the vial. The aqueous solution with different stabilizer 
candidates with predetermined concentrations was prepared and stirring overnight. The vial was 
vortex 5 seconds and sonication for 10 seconds, then vortex 5 seconds again. All the suspensions 
were keep still and stored at room temperature for 4 hours, then repeated the suspension 
processing. The 40 µl re-suspended suspension was transferred into one well of the 96-well plate 
for further investigation. Maximum 96 samples can be tested at one time. 
4.2.2.3 Polarized Light Microscopy 
The Nikon Ti Eclipse PLM was utilized as a new platform to characterize the particle 
size, particle size distribution and physical status of solid dispersion in this study. The 
background was adjusted to blue for the particle size characterization, while red background was 
used for the recrystallization detection. The stage holding a 96-well plate was programmed to 
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move from one well to another, and in every single well area, 3 pictures would be taken at 3 
random spots. In every picture, a binary system was created by the software using a binary 
threshold point so that the particles could be separated from the background. All the particle 
diameter, area would be noted and generated a particle size or area distribution.  
4.2.2.4 Powder X-ray diffraction (PXRD) 
Crystallinity of spray-dried powders was tested using a benchtop X-ray diffractometer 
(Rigaku Corp.) to obtain diffraction patterns. The diffractometer was able to generate Cu-ka 
radiation with current of 10 mA and voltage of 30 kV. A scan rate of 0.5/min with steps of 2u 
from 5 to 40 was used for all the scans performed. 
4.2.2.5 Modulated differential scanning calorimetry (mDSC) 
The suspension was kept still for 4 hours and then transferred into a centrifuge tube filter 
(0.22 µm cellulose acetate film) to centrifuge for 15 min under 15k rpm. The separated particles 
was dried in the 40 °C vacuum oven for 12 hours for mDSC test.  mDSC was conducted by 
weighing approximately 2-4 mg of spray dried powder, pre-dried powder, polymer, compound, 
or polymer/compound physical mixture in a standard DSC pan. The samples were heated at a 
rate of 2 C/min from 4 C to 200 C at a modulating oscillatory frequency of 0.83 C/80 s in a 
differential scanning calorimeter (TA Instruments, U.S.). The thermograms were recorded and 
glass transition temperatures (Tg) were analyzed using Universal Analysis software (TA 
Instruments). 
4.3 Results and Discussion 
4.3.1 Surfactant group 
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Figure 4-2. Polarized light microscopy images of re-suspended HPMCAS-INDO suspension 
with surfactant stabilizer with different concentrations for characterization of recrystallization. 
 
In the surfactant group, taurocholic acid sodium(TAS), sodium dodecyl sulfate(SDS), 
Pluronic® F-127 and polysorbate 80(TWEEN 80) were tested as suspension stabilizer for the 
suspension of spray dried particles of  HPMCAS-INDO, at 0.1, 0.2 and 0.5% w/v concentrations 
respectively. From figure 4-1, all samples in surfactant 0.1 and 0.2% groups showed needle 
shape crystalline particles or birefringence particles.  
However, for the samples with 0.5% of all these surfactant stabilizers, no needle shape 
crystalline particles or birefringence particles were observed. The in suspension with 0.5% SDS, 
all particles dissolved into the aqueous medium, and the suspension turned into clear solution. 
This is due to the increasing pH values caused by higher concentration of SDS increased the 
solubility of HPMCAS and also solubilized the drug. 
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4.3.2 Cellulosic group 
In the polymer stabilizer groups, hydroxypropyl methylcellulose (HPMC E5), 
methylcellulose (MC), hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (Kollidon PVP-
K30), vinylpyrrolidone-vinyl acetate copolymer (Kollidon VA64), polyvinyl caprolactam-
polyvinyl acetate-polyethylene glycol graft copolymer ( Soluplus®) were tested as suspension 
stabilizer for the suspension of spray dried particles of  HPMCAS-INDO, at 0.1, 0.5 and 1% w/v 
concentrations respectively. All samples in the polymer stabilizer groups did not show any 
needle shape crystalline indicating that all candidates had strong recrystallization inhibition 
effect for the ASD suspension. However, from the DSC thermograms, the samples with HPC 
showed small melting peak which is an evidence of recrystallization. Comparing with other 
polymer candidates, HPC has less hydrophobic function groups which means level of molecular 
interaction with the hydrophobic drug could be lower. Though the drug did not release and 
recrystallization did not happen in the solution, the phase separation and recrystallization could 
still happen.  
4.3.3 Particle size characterization 
The stabilizer candidates could inhibit recrystallization in the suspension for 4 hours were 
chosen for further investigation of preventing aggregation of the particles. The % of particle with 
size (area) larger than 100 µm2 was calculated and compared within all stabilizer and 
concentrations (ANOVA applied to test the significant difference followed by a two tailed 
student’s T test, p=0.05). From figure 4-5, TAS showed best ability to prevent the particles 
aggregation. The 0.1% MC inhibit the aggregation to less than 5%, but as the concentration 
increasing, more particles grouped up forming large agglomeration. The 1% MC solution has 
higher viscosity which could hinder the dispersion of the particles in the suspension.  
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4.3.4 Other ASDs systems 
For the other model drug ketoconazole, there were no needle shape crystalline particles or 
birefringence particles observed under the polarized light microscopy, even when DSC data 
indicated the existing of recrystallization. This Nikon Ti PLM platform might not be suitable to 
characterize all the recrystallization in the ASD suspension, but still could be used to investigate 
the particles aggregation. 
4.4 Conclusion 
The Nikon Ti PLM equipped with automatic stage is a powerful tool to characterize the 
particle size of the ASD suspensions, and can also serve as a screening tool for the suspension 
stabilizers. 
Taurocholic acid sodium(TAS), hydroxypropyl methylcellulose (HPMC E5), 
methylcellulose (MC), polyvinylpyrrolidone (Kollidon PVP-K30), vinylpyrrolidone-vinyl 
acetate copolymer (Kollidon VA64), polyvinyl caprolactam-polyvinyl acetate-polyethylene 
glycol graft copolymer ( Soluplus®) can be used as recrystallization inhibitor for the ASD 
suspensions even at low concentration (0.1%). But at 1% concentration, MC accelerated the 
aggregation which might affect the dissolution and bioavailability of the suspensions. For the 
surfactant candidates, due to the increased pH values and increased solubility for drug, surfactant 
might not be proper stabilizer to be used in ASD suspensions. 
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Figure 4-3. DSC thermograms for HPMCAS-INDO dried particle from the suspension with 
different concentrations of SDS. 
 
Figure 4-4. DSC thermograms for HPMCAS-INDO dried particle from the suspension with 
different concentrations of F-127. 
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Figure 4-5. DSC thermograms for HPMCAS-INDO dried particle from the suspension with 
different concentrations of TW80. 
 
Figure 4-6. DSC thermograms for HPMCAS-INDO dried particle from the suspension with 
different concentrations of TAS. 
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Figure 4-7. DSC thermograms for HPMCAS-INDO dried particle from the suspension with 1% 
polymer stabilizers. 
 
 
Figure 4-8. Polarized light microscopy images of re-suspended HPMCAS-INDO suspension 
with cellulosic polymer stabilizers with different concentrations for characterization of particle 
size. 
 57 
 
 
 
Figure 4-9. Polarized light microscopy images of re-suspended HPMCAS-INDO suspension 
with vinyl polymer stabilizers and TAS with different concentrations for characterization of 
particle size. 
 
Figure 4-10.  PLM images of the HPMCAS-INDO spray dried particles in 0.1% HPMC 
suspension medium (left) and binary system (right). 
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Figure 4-11. Drug released after 24 hours storage of the suspension with different surfactant 
stabilizer, DI water and pH=3 HCl suspension medium. 
 
Figure 4-12. pH values of suspension medium with surfactant stabilizers with different 
concentrations. 
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Figure 4-13. Drug released after 24 hours storage of the suspension with different polymer 
stabilizers. 
 
Figure 4-14. pH values of suspension medium with polymer stabilizers with different 
concentrations. 
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Figure 4-15. Statistical analysis results for aggregation inhibition ability of stabilizer candidates. 
 
Figure 4-16. Polarized light microscopy images of re-suspended HPMCAS-KETO suspension 
with different stabilizers with different concentrations. 
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Figure 4-17. Polarized light microscopy images of re-suspended EUDRAGIT-INDO suspension 
with different stabilizers. 
 
Figure 4-18. Polarized light microscopy images of re-suspended PVAP-INDO suspension with 
different stabilizers. 
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CHAPTER 5 
A DESIGN OF EXPERIMENT APPROACH FOR THE INFLUENCE OF PROCESSING 
PARAMETERS ON MELT-EXTRUDED SOLID DISPERSIONS 
 
5.1 Introduction 
Quality by Design (QbD) is a concept first outlined by quality expert Joseph M. Juran in 
publications, most notably Juran on Quality by Design. Designing for quality and innovation is 
one of the three universal processes of the Juran Trilogy, in which Juran describes what is 
required to achieve breakthroughs in new products, services, and processes. Juran believed that 
quality could be planned, and that most quality crises and problems relate to the way in which 
quality was planned. 
While Quality by Design principles have been used to advance product and process 
quality in industry, and particularly the automotive industry, they have also been adopted by the 
U.S. Food and Drug Administration (FDA) for the discovery, development, and manufacture of 
drugs. 
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Figure 5-1. Key steps in implementation of QbD for pharmaceutical product. 
 
Pharmaceutical QbD requires a thorough understanding of the product and the process, 
along with the knowledge of the relationship between the critical quality attributes (CQAs) and 
the clinical performance of the product. With the concept of QbD, a maximally efficient, agile, 
flexible pharmaceutical manufacturing sector that reliably produces high quality drug products 
without extensive regulatory oversight can be achieved. 
The effect of individual process parameters on the final product’s CQAs is studied with 
the help of statistical design of experiments (DoE) through which an operational design space 
(DS) is established. As a result of this, a range of variability is defined for each variable under 
which the CQAs remain within the pre-established limits. Thus, a controlled DS is generated for 
the process. Although adapting QbD methodology could be cumbersome initially, it will 
eventually increase the robustness and quality of the product. It will also reduce overall waste 
produced during manufacturing, as well as allow efficient globalization for companies with 
manufacturing sites across the world. 
In the QbD system, Design of Experiment (DoE) is most important part since the 
traditional changing of one factor at a time is not an efficient and economic strategy. The 
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traditional experimental plan does not give any information about the position of the optimum 
and can, at its best, lead only to a local optimum of the system and is based on large number of 
experiments and often relies merely on the experience of the analyst. The one-at-a-time 
optimization also ignores interactions between factors and calls for unnecessarily numerous runs. 
With rapidly rising costs of experiments, it is very important that the development and 
optimization of any experimental plan is done with as few experiments and with as low costs as 
possible. 
The present study was a Design of Experiment approach, or partial QbD (quality by 
design) approach to understand the effect of processing parameters on immediate release melt-
extruded solid dispersions. The DoE approach was applied to melt extrusion and processing with 
Soluplus® for solubility enhancement using fenofibrate as a poorly soluble API. 
5.2 Material and methods 
5.2.1 Materials  
Soluplus, a hydrophilic graft copolymer of polyvinyl caprolactam–polyvinyl acetate–
polyethylene was kindly donated by BASF Corporation (Florham Park, NJ). Fenofibrate was 
purchased from Letco Medical (Decatur, AL). Avicel PH-102 (microcrystalline cellulose, 
USP/NF) was donated by FMC Biopolymer (Philadelphia, PA). Magnesium stearate, USP/NF 
was purchased from Spectrum Chemicals Corporation (Gardena, CA). All other materials 
utilized in the study were of ACS grade or higher and purchased from Fisher Scientific (Pittsburg, 
PA). Dissolution enhancing additives utilized in this study were milled with a Fitzpatrick L1A 
Fitzmill (Fitzpatrick, Elmhurst, IL). Powder passing through a 0.149 mm sieve and retained on a 
0.074 mm sieve were used in tablet formulation studies. 
5.2.2 Methods 
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5.2.2.1 Design of Experiment 
A Box-Behnken design at three factors(feeding rate, screw speed, temperature) with three 
levels was prepared by Design Expert® (version 8.06, Stat-Ease Inc.) for quantitative risk 
evaluation, optimization the processing parameters and identify the design space. The milling 
efficiency and percentage of drug released at 30 min were chosen as response values. The central 
point run was repeated 5 times, resulting in a totally 17 runs for one design. The same design 
method was also applied to milling processing and tablet compression for the optimization of the 
processing parameters and defines the design space. 
5.2.2.2 Hot melt extrusion 
Amorphous solid dispersions of fenofibrate and Soluplus was prepared utilizing HME 
technology. Thermal gravimetric analysis (TGA) and differential scanning calorimetry (DSC) 
were utilized to determine the extrusion processing temperature range, and the actual extrusion 
parameters were given by the DOE software. The API and polymer were mixed in a V-cone 
blender (MaxiBlendTM, GlobePharma) at 20 rpm for 5 min and then extruded with a co-rotating 
twin-screw extruder (Process 11, ThermoFisher Scientific) into uniform rod extrudates. 
5.2.2.4 Statistical analysis 
The results obtained are expressed as a mean ± standard deviation calculated using 
Microsoft Excel (Redmond, WA, USA) software. Statistical analysis was performed using SPSS 
version 15.0 for windows (SPSS, Inc, Chicago, IL, USA). One-way ANOVA followed by the 
Tukey multiple comparisons were used to compare the results. A p value of less than 0.05 was 
considered as statistically significant. 
5.2.2.5 Thermal gravimetric analysis (TGA) 
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TGA studies were performed on Perkin Elmer Pyris 1 TGA with the PyrisTM software 
(PerkinElmer Life and analytical sciences, CT, USA). 3-5 mg of the sample was weighed and 
heated from 20 °C to 300 °C under an inert nitrogen atmosphere at a flow rate of 20 °C/min. 
Percent weight loss was plotted against temperature to determine the weight loss. The TGA 
sample of fenofibrate was holding at the highest extrusion temperature (145 °C) for 15 min to 
test the thermal stability. 
5.2.2.6 Differential scanning calorimetry (DSC) 
DSC (Perkin Elmer, Diamond DSC) was utilized to measure the melting enthalpy of the 
solid dispersions. Samples were weighed (3-5 mg) in an aluminum sample pan and hermetically 
sealed at each time point using a heating rate of 20°C/min from 30°C to 200°C under an inert 
nitrogen atmosphere at a flow rate was 20 mL/min. An empty pan was used as reference. 
Measurements were repeated three times. An Indium standard was used for calibration. 
5.2.2.7 HPLC-UV Analysis  
A Waters HPLC-UV system (Waters Corp, Milford, MA), equipped with a Luna 5um C18 
100Å  column (Phenomenex, US), was used to detect fenofibrate at a wavelength of 286 nm. The 
mobile phase consisted of acetonitrile and phosphoric acid in water (pH=2.5) at a ratio of 85:15 
(v/v). The flow rate was maintained at 1.0 mL/min. The injection volume was 20 μL. The 
observed retention time of fenofibrate was 6 min. The data was acquired and processed using 
Waters Empower 3 software suite. 
5.2.2.8 Scanning electron microscopy (SEM) 
SEM was used to study surface morphology of the solid dispersions.  Samples were 
mounted on aluminum stubs held with a carbon adhesive film. Gold was used to coat the 
Samples by a Hummer® 6.2 sputtering system (Anatech LTD, VA, USA) in a high vacuum 
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evaporator. The surface topography of the sample was analyzed by a scanning electron 
microscope operating at an accelerating voltage from 1.0 kV to 5.0 kV (JEOL JSM-5600).  
5.3 Results and Discussion 
During the hot melt extrusion processing, achieving the amorphous solid dispersion is the 
primary target. To convert the crystalline drug into amorphous state, the extrusion temperature 
should be near or higher than the melt temperature of the drug. If using temperature lower than 
the melting point of the drug, the screw configuration and screw speed need to be optimized to 
generate enough shear for the high energy input for the drug. At same time, low extrusion 
temperature might cause failure of the processing due to high torque. If the extrusion temperature 
is close to or lower than the glass transition temperature of the binary formulation, the high 
viscosity could lead to high torque. However, if both high temperature and high shear are applied 
to the formulation, degradation could happen which would increase the impurities in the 
extrudate. Even the formulation is thermostable, too high extrusion could also result in liquidize 
extrudate or sticky formulations which is difficult to handle for the downstream processing. 
5.3.1 The Design of Experiment method 
In this study, a Box-Behnken design was utilized to qualitatively and quantitatively 
evaluate the effect of different critical quality attributes on the product quality attributes. The 
Box-Behnken design is an independent quadratic design, not like other design methods, for 
example: fractional factorial design or central composite design, in that it does not contain any 
embedded factorial or fractional factorial design. The treatment combinations are at the 
midpoints of edges of the process space and at the center when using the Box-Behnken design. 
These designs are rotatable (or near rotatable) and require 3 levels of each factor. The designs 
have limited capability for orthogonal blocking compared to the central composite designs. 
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Figure 5-2. Experimental layout by Box-Behnken Design. 
 
Table 5-1. Intermediate Product Quality Profile. 
Product Attribute  Target 
Content uniformity (CU) 
Conforms to USP<905> Uniformity of Dosage 
Units 
Percentage of crystalline API 0% ( 100% amorphous) 
Degradation product   Total impurities: NMT 1.0%  
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Table 5-2. Target Product Quality Profile. 
Product Attribute  Target 
Content uniformity (CU) Conforms to USP<905> Uniformity of Dosage Units 
Dissolution behavior  NLT 80% of label amount released at 30 min    
Degradation product   Total impurities: NMT 1.0%  
 
The milled solid dispersion particles serving as an intermediate product for the target 
product should meet the target profile, like total impurities no more than 1%, immediate drug 
release, content uniformity (Table 5-1). In the R1: disso ANOVA table, values of "Prob > F" less 
than 0.0500 indicate model terms are significant. In this case A, B, C, BC are significant model 
terms which means feed rate, temperature, screw speed and interaction between temperature and 
screw speed are significant. However, the p value for screw speed was very close to 0.05 which 
means the impact of this factor is statistically significant but not huge. The 3D response surface 
also indicated that temperature was more significant.   
Table 5-3. ANOVA for response surface quadratic model for response value 1. 
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Table 5-4. ANOVA for response surface quadratic model for response value 2. 
 
5.3.2 The effect of HME processing parameters on the dissolution rate 
The temperature showed more significant effect on the 30 min’s dissolution when the 
feed rate is high comparing with the low feed rate runs. And the feed rate exhibited more 
significant effect on the 30 min’s dissolution when temperature is low. This is because that when 
feed rate is low, even low temperature can provide enough energy input to completely melt the 
API and polymer carrier, so that the drug is easier to be dispersed homogenously into the whole 
polymeric matrix. The evenly dispersed system can avoid the existing of drug rich zones in the 
solid dispersion which could avoid the amorphous drug recrystallization during the dissolution.   
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Figure 5-3.  The 3D response surface of feed rate and temperature for response value R1. 
 
Figure 5-4.  The 3D response surface of feed rate and screw speed for response value R1. 
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Figure 5-5.  The 3D response surface of temperature and screw speed for response value R1. 
 
 
 
Figure 5-6. The 2D design space of temperature and feed rate with screw speed at 100 rpm for 
response value R1. 
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5.3.3 The effect of HME processing parameters on the milling efficiency 
In this study, the melt-extruded solid dispersion was an intermediate product and the 
assuming final dosage form was tablet. So the extrudate should be milled and sieved, then blend 
with other excipients for tablet compression. To maximum the productivity, milling efficiency 
(ME=weight of sample passed milling sieve/input weight×100%) became a factor with great 
importance. In the R2: ME ANOVA table, feed rate and temperature showed significant effect 
on the response value. Low feeding rate and high temperature could result in high ME. 
The temperature showed more significant effect on the milling efficiency when the feed 
rate is high comparing with the low feed rate runs. And the feed rate exhibited more significant 
effect on the milling efficiency. But overall speaking, the low feed rate could increase the milling 
efficiency of the melt extrudate. When materials extruded through the small size rod die, 
pressure was built up mainly depend on how much material fed and pushed forward along the 
screws. The higher the feed rate is, the higher pressure would be build up inside the concave of 
the die. This could result in the melt extruded solid dispersion with higher density, or higher 
physical strength. 
 
Figure 5-7.  The 3D response surface of feed rate and temperature for response value R2. 
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Figure 5-8.  The 3D response surface of feed rate and screw speed for response value R2. 
 
Figure 5-9.  The 3D response surface of temperature and screw speed for response value R2. 
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Figure 5-10. The 2D design space of temperature and feed rate with screw speed at 100 rpm for 
response value R2. 
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CHAPTER 6 
SUMMARY AND CONCLUSIONS 
 
6.1 Summary 
Over the last few decades, hot-melt extrusion (HME) has been well adapted into the 
pharmaceutical industry to enhance the solubility and bioavailability of poorly water soluble 
compounds by producing amorphous solid dispersions. It is critical to evaluate and enhance the 
physical stability of the amorphous solid dispersion during commercializing the drug product 
with hot melt extrusion technology. Additionally, processing parameters also play an important 
role in the formulation development utilizing HME. 
In Chapter 2, The improved Avrami equation demonstrated more accurate evaluation for 
all of the solid dispersion systems investigated in this study. This is particularly evident for the 
late stages of the recrystallization process, which provides a novel approach for early stage 
formulation development of amorphous solid dispersion systems. This can be viewed as both 
time and cost effective when compared to the conventional ICH stability tests. By resolving the 
relationships between the recrystallization rate constant, temperature, relative humidity and 
formulation, an accurate and reliable prediction can be obtained in reference to recrystallization 
kinetics. The polymers (Klucel™ EF/LF/ELF) inhibited the recrystallization process of the 
amorphous API and HPC grades with a higher molecular weight exhibited more favorable 
results. The method utilized in this study would also be useful for screening the most suitable 
polymeric carrier and other excipients in solid dispersion systems. 
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In Chapter 3, HPC-FF, EC-FF and PEG-FF amorphous solid dispersion systems were 
successfully prepared by HME technology. This is the first time that the moisture sorption 
abilities of amorphous solid dispersions prepared by hot melt extrusion technology with different 
polymeric carriers has been reported. Also, this study investigated the moisture sorption from 
both the formulation as well as processing approaches, which are very limited as reported in 
previous literature. The nature of the polymer, molecular weight of the polymer, HME process 
and downstream processing parameters were found to have a significant effect on the moisture 
sorption ability of the amorphous solid dispersion systems.  
In Chapter 4, The Nikon Ti PLM equipped with automatic stage is a powerful tool to 
characterize the particle size of the ASD suspensions, and can also serve as a screening tool for 
the suspension stabilizers. Taurocholic acid sodium(TAS), hydroxypropyl methylcellulose 
(HPMC E5), methylcellulose (MC), polyvinylpyrrolidone (Kollidon PVP-K30), 
vinylpyrrolidone-vinyl acetate copolymer (Kollidon VA64), polyvinyl caprolactam-polyvinyl 
acetate-polyethylene glycol graft copolymer ( Soluplus®) can be used as recrystallization 
inhibitor for the ASD suspensions even at low concentration (0.1%). But at 1% concentration, 
MC accelerated the aggregation which might affect the dissolution and bioavailability of the 
suspensions. For the surfactant candidates, due to the increased pH values and increased 
solubility for drug, surfactant might not be proper stabilizer to be used in ASD suspensions. 
In Chapter 5, a Design of Experiment approach, or partial QbD (quality by design) 
approach to understand the effect of processing parameters on immediate release melt-extruded 
solid dispersions. The DoE approach was applied to melt extrusion and processing with 
Soluplus® for solubility enhancement using fenofibrate as a poorly soluble API. The feed rate 
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and temperature were found to have more significant effect on the milling efficiency and 
dissolution at 30 min.  
6.2 Future Prospective 
 Investigate the possibility of including a correction factor of RH into the 
improved Avrami equation, so that the equation can be used to determine the recrystallization 
rate constant for a certain condition (both RH and temperature). 
 Employ Quality by Design and Risk Assessment to have a systematical 
understanding of the quality of the hot melt extruded solid dispersion product.  
 Use the polarized microscopy system to do the high throughput solid dispersion 
formulation screening. 
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